
Neurocrine Biosciences (NBIX): Growth Franchise With Pipeline Upside
Neurocrine Biosciences pairs a profitable commercial base with accelerating sales from INGREZZA, CRENESSITY, and newly acquired VYKAT XR. The stock screens as a Buy on strong revenue growth, solid cash generation, and a broad late-stage pipeline.


